Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone858-617-7600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$451.24 million
Profitability
Miscellaneous
Employees585
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions
What is Neurocrine Biosciences' stock symbol?
Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."
How were Neurocrine Biosciences' earnings last quarter?
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings results on Monday, July, 29th. The company reported $0.37 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.24 by $0.13. The firm earned $183.58 million during the quarter, compared to analysts' expectations of $161.79 million. Neurocrine Biosciences had a net margin of 2.98% and a return on equity of 0.46%. Neurocrine Biosciences's quarterly revenue was up 89.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.07) EPS. View Neurocrine Biosciences' Earnings History.
When is Neurocrine Biosciences' next earnings date?
What price target have analysts set for NBIX?
19 Wall Street analysts have issued 1 year price objectives for Neurocrine Biosciences' shares. Their predictions range from $84.00 to $135.00. On average, they expect Neurocrine Biosciences' stock price to reach $106.5556 in the next year. This suggests a possible upside of 4.3% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.
What is the consensus analysts' recommendation for Neurocrine Biosciences?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 3 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.
What are Wall Street analysts saying about Neurocrine Biosciences stock?
Here are some recent quotes from research analysts about Neurocrine Biosciences stock:
- 1. According to Zacks Investment Research, "Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes. " (7/31/2019)
- 2. HC Wainwright analysts commented, "Our price target of $102/share is based on an equally weighted composite of: (a) $103/share, as a 35x multiple of taxed and diluted FY25 GAAP EPS of $8.80 discounted back to and (b) an NPV of $101/share (discount rate 10%, growth rate 2%). We base our valuation on a 20% royalty on sales for Elagolix in endometriosis and uterine fibrosis (probability adjusted). For valbenazine, we include the indication of TD. For opicapone, we include the US revenue (63% goes to 85% POS." (1/30/2019)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $121 PT on NBIX. Voyager (VYGR, NC) announced a collaboration to develop four of Voyager’s assets, including those for Friedrich’s Ataxia. We believe this deal brings value to both partners, allowing Neurocrine to expand its platform to innovative gene therapy treatments, while it continues to focus on realizing clinical and commercial synergies in movement disorders (and also possibly to expand to additional indications that may be served by Voyager’s platform). We also opine that Voyager benefits from a partner with significantly more resources and expertise in clinical development and commercialization." (1/29/2019)
Has Neurocrine Biosciences been receiving favorable news coverage?
News headlines about NBIX stock have trended negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neurocrine Biosciences earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Neurocrine Biosciences.
Who are some of Neurocrine Biosciences' key competitors?
Some companies that are related to Neurocrine Biosciences include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), BIO-TECHNE (TECH), bluebird bio (BLUE), Moderna (MRNA), Adaptive Biotechnologies (ADPT), argenx (ARGX), Repligen (RGEN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Ablynx (ABLYF), Crispr Therapeutics (CRSP) and Iovance Biotherapeutics (IOVA).
What other stocks do shareholders of Neurocrine Biosciences own?
Who are Neurocrine Biosciences' key executives?
Neurocrine Biosciences' management team includes the folowing people:
- Dr. Kevin C. Gorman, CEO & Director (Age 61)
- Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)
- Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)
- Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)
- Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62)
Who are Neurocrine Biosciences' major shareholders?
Neurocrine Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (10.21%), Vanguard Group Inc. (8.86%), Perceptive Advisors LLC (4.39%), Price T Rowe Associates Inc. MD (3.69%), First Trust Advisors LP (1.40%) and Point72 Asset Management L.P. (1.23%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.
Which institutional investors are selling Neurocrine Biosciences stock?
NBIX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Renaissance Technologies LLC, Price T Rowe Associates Inc. MD, Braun Stacey Associates Inc., AQR Capital Management LLC, Cormorant Asset Management LP, Vanguard Group Inc. and Handelsbanken Fonder AB. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy and Richard F Pops. View Insider Buying and Selling for Neurocrine Biosciences.
Which institutional investors are buying Neurocrine Biosciences stock?
NBIX stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Point72 Asset Management L.P., Janus Henderson Group PLC, Perceptive Advisors LLC, First Trust Advisors LP, Holocene Advisors LP, Brown Advisory Inc. and D. E. Shaw & Co. Inc.. View Insider Buying and Selling for Neurocrine Biosciences.
How do I buy shares of Neurocrine Biosciences?
Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Neurocrine Biosciences' stock price today?
One share of NBIX stock can currently be purchased for approximately $102.20.
How big of a company is Neurocrine Biosciences?
Neurocrine Biosciences has a market capitalization of $9.36 billion and generates $451.24 million in revenue each year. The company earns $21.11 million in net income (profit) each year or $0.22 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.View Additional Information About Neurocrine Biosciences.
What is Neurocrine Biosciences' official website?
How can I contact Neurocrine Biosciences?
Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]
MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
